Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23770531 | 0.91 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14154473 | 0.89 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14112074 | 0.83 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL8556730 | 0.82 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL3819419 | 0.81 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL13664908 | 0.77 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14112076 | 0.75 | HSD11B1 (0.46) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL14307799 | 0.75 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6396217 | 0.73 | SIGMAR1 (0.52) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 | |
| SCHEMBL9479601 | 0.72 | CYP2D6 (0.54) | SIGMAR1ALDH1A1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253621-A1 | CD73 INHIBITORS AND THERAPEUTIC USES THEREOF | ENTPD5, ENTPD1, NT5E | SIGMAR1 4584/4885ALDH1A1 205/4885TP53 1079/4885 |
| US-11332492-B2 | CD73 inhibitors and therapeutic uses thereof | ENTPD5, ENTPD1, NT5E | SIGMAR1 4584/4885ALDH1A1 205/4885TP53 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.